Fulvestrant Accord 250 mg/5 ml Solution injectable dans une seringue Préremplie Elveția - italiană - Swissmedic (Swiss Agency for Therapeutic Products)

fulvestrant accord 250 mg/5 ml solution injectable dans une seringue préremplie

Fulvestrant Xiromed 250 mg/5 ml Injektionslösung in einer Fertigspritze Elveția - italiană - Swissmedic (Swiss Agency for Therapeutic Products)

fulvestrant xiromed 250 mg/5 ml injektionslösung in einer fertigspritze

Fulvestrant Xiromed 250 mg/5 ml Solution injectable dans une seringue Préremplie Elveția - italiană - Swissmedic (Swiss Agency for Therapeutic Products)

fulvestrant xiromed 250 mg/5 ml solution injectable dans une seringue préremplie

Fulvestrant Zentiva 250 mg/5 ml Injektionslösung in einer Fertigspritze Elveția - italiană - Swissmedic (Swiss Agency for Therapeutic Products)

fulvestrant zentiva 250 mg/5 ml injektionslösung in einer fertigspritze

Fulvestrant Zentiva 250 mg/5 ml Solution injectable dans une seringue Préremplie Elveția - italiană - Swissmedic (Swiss Agency for Therapeutic Products)

fulvestrant zentiva 250 mg/5 ml solution injectable dans une seringue préremplie

Fulvestrant Labatec 250 mg/5 ml Solution pour injection en seringue pré-remplie Elveția - italiană - Swissmedic (Swiss Agency for Therapeutic Products)

fulvestrant labatec 250 mg/5 ml solution pour injection en seringue pré-remplie

Fulvestrant Labatec 250 mg/5 ml Solution pour injection en seringue pré-remplie Elveția - italiană - Swissmedic (Swiss Agency for Therapeutic Products)

fulvestrant labatec 250 mg/5 ml solution pour injection en seringue pré-remplie

Ibrance Uniunea Europeană - italiană - EMA (European Medicines Agency)

ibrance

pfizer europe ma eeig  - palbociclib - neoplasie al seno - agenti antineoplastici - ibrance è indicato per il trattamento di ormone recettore (hr) positivo, human epidermal growth factor receptor 2 (her2 negativo del carcinoma localmente avanzato o metastatico cancro al seno:in combinazione con un inibitore dell'aromatasi;in combinazione con fulvestrant in donne che hanno ricevuto una precedente terapia endocrina. in pre - o perimenopausal donne, la terapia ormonale dovrebbe essere combinato con un rilascio dell'ormone luteinizzante (lhrh) agonista.

Verzenios Uniunea Europeană - italiană - EMA (European Medicines Agency)

verzenios

eli lilly nederland b.v. - abemaciclib - neoplasie al seno - agenti antineoplastici - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.

Piqray 150 mg Compresse rivestite con film Elveția - italiană - Swissmedic (Swiss Agency for Therapeutic Products)

piqray 150 mg compresse rivestite con film

novartis pharma schweiz ag - alpelisibum - compresse rivestite con film - alpelisibum 150 mg, cellulosum microcristallinum, mannitolum, carboxymethylamylum natricum un corrisp. sodio 0.63 mg, hypromellosum, magnesio stearas, Überzug: hypromellosum, macrogolum, talco, e 171, e 172, per compresso haze. - in combinazione con fulvestrant per il trattamento di hr-positivo, her2-negativo carcinoma mammario avanzato con mutazione pik3ca - synthetika